Perspective Therapeutics, Inc. last reported quarterly results on Aug 10, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$0.22. It usually reports 9–41 days after a quarter ends. Based on that pattern, the next release is estimated for around Oct 19, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Monday. Based on last year's release for the same quarter on Oct 20, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 9–41 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 10, 2026
41 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-27
-24.7%
|
-0.22
+24.1%
|
|
May 4, 2026
34 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-26
-44.1%
|
-0.25
+0.0%
|
|
Jan 9, 2026
9 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
—
|
-37
+6.7%
|
-0.50
+11.2%
|
|
Oct 20, 2025
20 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-26
-71.7%
|
-0.35
-66.7%
|
|
Aug 13, 2025
44 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-21
-83.6%
|
-0.29
-61.1%
|
|
May 12, 2025
42 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-18
-48.0%
|
-0.25
+0.0%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-40
-62.8%
|
-0.57
|
|
Nov 12, 2024
43 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
—
|
-15
-46.0%
|
-0.21
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CATX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 728387
- Former names
- IsoRay, Inc. (until Feb 16, 2023); Isoray, Inc. (until Feb 16, 2023); CENTURY PARK PICTURES CORP (until Aug 3, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.